Evaluation of blockbuster drugs under the rule-of-five

Pharmazie

Volumn 65, Issue 2, 2010, Pages 148-152

  Gimenez B G ^a   Santos, M S ^a   Ferrarini, M ^b   Dos Santos Fernandes, João Paulo ^a,b  

^a Centro Universitario Sao Camilo   (Brazil)

^b Universidade do Grande ABC   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG ABSORPTION; DRUG PENETRATION; DRUG RESEARCH; DRUG SCREENING; MOLECULAR WEIGHT; RULE OF FIVE;

CHEMISTRY, PHARMACEUTICAL; COMBINATORIAL CHEMISTRY TECHNIQUES; DATABASES, FACTUAL; DRUG EVALUATION, PRECLINICAL; HYDROGEN BONDING; MOLECULAR WEIGHT; PERMEABILITY; PHARMACOKINETICS;

EID: 76149112902     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2010.9733     Document Type: Article

References (30)

1. Biswas D, Roy S, Sen S (2006) A simple approach for indexing the oral druglikeness of a compound: discriminating druglike compounds from nondruglike ones. J Chem Inf Model 46: 1394-1401.
2. th ed., New York, pp. 1-39.
3. Clark DE (1999) Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J Pharm Sci 88: 807-814.
4. DiMasi JA (1995) Success rates for new drugs entering clinical testing in the United States. Clin Pharmacol Ther 58: 1-14.
5. Gershell LJ, Atkins JH (2003) A brief history of novel drug discovery technologies. Nat Rev Drug Discov 2: 321-327.
6. Ghose AK, Viswanadhan VN, Wendoloski JJ (1999) A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1.Aqualitative and quantitative characterization of known drug databases. J Comb Chem 1: 55-68.
7. Hansch C, Leo A, Hoekman D (1995) Exploring QSAR: hydrophobic, electronic and steric constants, Washington.
8. HenryDR(2004) Combinatorial chemistry. In: Block JH, Beale JM Jr (eds.). Wilson and Gisvold's textbook of organic medicinal and pharmaceutical chemistry, Philadephia, pp. 43-64.
9. IMS Health Institute (2008) Top Global Pharmaceutical Products 2007, Norwalk, CT.
10. Keller TH, Pichota A, Yin Z (2006) A practical view of 'druggability'. Curr Opin Chem Biol 10: 357-361.
11. Klopman G, Li J, Wang S, Dimayuga M (1994) Computer automated log p calculations based on an extended group contribution approach. J Chem Inf Comput Sci 34: 752-781.
12. Leeson PD, Springthorpe B (2007) The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 6: 881-890.
13. Lima LM (2007) Química Medicinal Moderna: Desafio e Contribuição Brasileira. Quim Nova 30: 1456-1468.
14. Lima LM, Barreiro EJ (2005) Bioisosterism: a useful strategy for molecular modification and drug design. Curr Med Chem 12: 23-49.
15. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23: 3-25.
16. Lu JJ, Crimin K, Goodwin JT, Crivori P, Orrenius C, Xing L, Tandler PJ, Vidmar TJ, Amore BM, Wilson AGE, Stouten PFW, Burton PS (2004) Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. J Med Chem 47: 6104-6107.
17. MarvinSketch version 5.2.3 (2007) ChemAxon, Ltd., Budapest, HUN.
18. Navia MA, Chaturvedi PR (1996) Design principles for orally bioavailable drugs. Drug Dev Today 1: 179-189.
19. Oprea TI, Allu TK, Fara DC, RadRF, Ostopovici L, BologaCG(2007) Lead-like, drug-like or "Pub-like": howdifferent are they? J Comput Aided Mol Des 21: 113-119.
20. Oprea TI, Davis AM, Teague SJ, Leeson PD (2001) Is there a difference between leads and drugs? A historical perspective. J Chem Inf Comput Sci 41: 1308-1315.
21. Overington JP, Al-Lazikani B, Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov 5: 993-996.
22. th ed., London.
23. Syracuse Research Corporation. Physical/Chemical Property Database (1994) SRC Environmental Science Center, Syracuse, NY.
24. Veber DF, Johnson SR, Cheng HY, Smith BR,WardKW, Kopple KD (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45: 2615-2623.
25. Vieth M, Sutherland JJ (2006) Dependence of molecular properties on proteomic family for marketed oral drugs. J Med Chem 49: 3451-3453.
26. Vistoli G, Pedretti A, Testa B (2008) Assessing drug-likeness - what are we missing? Drug Discov Today 13: 285-294.
27. Viswanadhan VN, Ghose AK, Revankar GR, Robins RK (1989) Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J Chem Inf Comput Sci 29: 163-172.
28. WaltersWP, Ajay A, MurckoMA(1999) Recognizing molecules with drug-like properties. Curr Opin Chem Biol 3: 384-387.
29. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M (2008) DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acid Res 36: D901-906.
30. Zhang M, Wilkinson B (2008) Drug discovery beyond the 'rule-of-five'. Curr Opin Biotech 18: 478-488.